Deferiprone. A review of its clinical potential in iron overload in β-thalassaemia major and other transfusion-dependent diseases

Drugs

Volumn 58, Issue 3, 1999, Pages 553-578

  Barman Balfour, Julia A ^a   Foster, Rachel H ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTINUCLEAR ANTIBODY; DEFERIPRONE; DEFEROXAMINE; FERRITIN; IRON; IRON CHELATING AGENT; LIVER ENZYME; ZINC;

AGRANULOCYTOSIS; ANTIOXIDANT ACTIVITY; AREA UNDER THE CURVE; ARTHROPATHY; BETA THALASSEMIA; BLOOD TRANSFUSION; BONE MARROW SUPPRESSION; CLINICAL TRIAL; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG ADMINISTRATION; DRUG BLOOD LEVEL; DRUG COMBINATION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG METABOLISM; FERRITIN BLOOD LEVEL; GASTROINTESTINAL SYMPTOM; HUMAN; IMMUNOPATHOLOGY; INTRAMUSCULAR DRUG ADMINISTRATION; IRON BINDING CAPACITY; IRON CHELATION; IRON METABOLISM; IRON OVERLOAD; LIVER TOXICITY; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PATIENT COMPLIANCE; PHARMACODYNAMICS; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SUBCUTANEOUS DRUG ADMINISTRATION; URINARY EXCRETION; ZINC DEFICIENCY;

BETA-THALASSEMIA; BLOOD TRANSFUSION; CLINICAL TRIALS; HUMANS; IRON; IRON CHELATING AGENTS; PYRIDONES;

EID: 0032887235     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199958030-00021     Document Type: Review

References (131)

1. Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood 1997 Feb 1; 89: 739-61
2. Porter JB. A risk-benefit assessment of iron-chelation therapy. Drug Saf 1997 Dec; 17 (6): 407-21
3. Hoffbrand AV, Wonke B. Iron chelation therapy. J Intern Med Suppl 1997; 740: 37-41
4. Gabutti V, Piga A. Results of long-term iron-chclating therapy. Acta Haematol 1996; 95: 26-36
5. Kattamis CA, Kattamis AC. Management of thalassemias: growth and development, hormone substitution, vitamin supplementation, and vaccination. Semin Hematol 1995 Oct; 32: 269-79
6. Giardina PJ, Grady RW. Chelation therapy in β-thalassemia: the benefits and limitations of desferrioxamine. Semin Hematol 1995 Oct; 32: 304-12
7. Aldouri MA, Wonke C, Hoffbrand AV, et al. Iron state and hepatic disease in patients with thalassaemia major, treated with long term subcutaneous desferrioxamine. J Clin Pathol 1987; 40: 1353-9
8. S. Mosby's complete drug reference. Physicians GenRx. 7th ed. St Louis (Mo): Mosby-Year Hook, 1997
9. British National Formulary. 37th ed. London: British Medical Association and the Royal Pharmaceutical Society of Great Britain, 1999
10. Porter JB, Huehns ER. The toxic effects of desferrioxamine. Baillieres Clin Haematol 1989; 2 (2): 459-74
11. Hoffbrand AV. Oral iron chelation, Semin Hematol 1996 Jan; 33: 1-8
12. Elorriaga R, Fernández Martin JL, Menéndez Fraga P, et al. Aluminium removal: short-and long-term preliminary results with L1 in rats. Drugs Today 1992; 28 Suppl. A: 177-82
13. Canteros-Piccotto MA, Fernández-Martin JL, Cannata-Ortiz MJ, et al. Effectiveness of deferiprone (L1) releasing the aluminium bound to plasma proteins in chronic renal failure. Nephrol Dial Transplant 1996 Jul; 11: 1488-9
14. Kontoghiorghes GJ, Barr J, Baillod RA. Aluminium mobilization in renal dialysis patients using the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1). Drugs Today 1992; 28 Suppl. A: 183-7
15. Kontoghiorghes GJ, Barr J, Baillod RA. Studies of aluminium mobilization in renal dialysis patients using the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one. Arzneimittel Forschung 1994 Apr; 44: 522-6
16. Sheppard LN, Kontoghiorghes GJ. Competition between deferiprone, desferrioxamine and other chelators for iron and the effect of other metals. Arzneimittel Forschung 1993 Jun; 43: 659-63
17. Eybl V, Svihovcová P, Koutensky J, et al. Interaction of L1, LINAII and deferoxamine with gallium in vivo. Drugs Today 1992; 28 Suppl. A: 173-5
18. Al-Refaie FN, Hoffbrand AV. Oral iron chelation therapy. Rec Adv Haematol 1993; 7: 185-216
19. 1) in patients with iron overload. Br J Haematol 1995 Feb; 89: 403-8
20. Kontoghiorghes GJ, Goddard JG, Bartlett AN, et al. Pharmacokinetic studies in humans with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one. Clin Pharmacol Ther 1990 Sep; 48: 255-61
21. Bergeron RJ, Streiff RR, Wiegand J, et al. A comparison of the iron-clearing properties of 1,2-dimethyl-3-hydroxypyrid-4-one, 1,2-diethyl-3-hydroxypyrid-4-one, and deferoxamine. Blood 1992 Apr 1; 79: 1882-90. [letter]
22. Venkataram S, Rahman YE. Studies of an oral iron chelator: 1,2-dimethyl-3-hydroxy-pyrid-4-one. I. Iron excretion in rats: development of a new rapid microwave method for iron analysis in faeces [see comments]. Br J Haematol 1990 Jun; 75: 274-7
23. Fassos FF, Berkovitch M, Daneman N, et al. Efficacy of deferiprone in the treatment of acute iron intoxication in rats. J Toxicol Clin Toxicol 1996 May; 34: 279-87
24. Hung O, Manoach S, Howland MA, et al. Deferiprone for acute iron poisoning [abstract]. J Toxicol Clin Toxicol 1997 Aug; 35: 565
25. Kontoghiorghes GJ, Aldouri MA, Sheppard L, et al. 1,2-Dimethyl-3-hydroxypyrid-4-one, an orally active chelator for treatment of iron overload. Lancet 1987 Jun 6; 1: 1294-5
26. Kontoghiorghes GJ, Aldouri MA, Hoffbrand AV, et al. Effective chelation of iron in β thalassaemia with the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one. Br Med J Clin Res Ed 1987 Dec 12; 295: 1509-12
27. 1, an oral iron chelator, in transfusion dependent thalassaemia: Indian trial. Br J Haematol 1992 Oct; 82: 460-6
28. Fassos FF, Klein J, Fernandes D, et al. Urinary iron excretion depends on the mode of administration of the oral iron chelator 1,2-dimethyl-3-hydoxypyrid-4-one in patients with homozygous β-thalassemia. Clin Pharmacol Ther 1994 Jan; 55: 70-5
29. Fassos FF, Klein J, Fernandes D, et al. The pharmacokinetics and pharmacodynamics of the oral iron chelator deferiprone (L1) in relation to hemoglobin levels. Int J Clin Pharmacol Ther 1996 Jul; 34: 288-92
30. Matsui D, Klein J, Hermann C, et al. Relationship between the pharmacokinetics and iron excretion pharmacodynamics of the new oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one in patients with thalassemia. Clin Pharmacol Ther 1991 Sep; 50: 294-8
31. Hornstein M, Sautjeaurostoker C, Peduzzi J, et al. Oxacillin-hydrolyzing beta-lactamase involved in resistance to imipenem in Acinetobacter baumannii. FEMS Microbiol Lett 1997 Aug 15; 153: 333-9
32. Stobie S, Tyberg J, Matsui D, et al. Comparison of the pharmacokinetics of 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in healthy volunteers, with and without co-administration of ferrous sulfate, to thalassemia patients. Int J Clin Pharmacol Ther Toxicol 1993 Dec; 31: 602-5
33. Zevin S, Link G, Grady RW, et al. Origin and fate of iron mobilized by the 3-hydroxypyridin-4-one oral chelators: studies in hyportransfused rats hy selective radioiron probes of reticuloendothelial and hepatocellular iron stores. Blood 1992 Jan 1; 79: 248-53
34. 59FE-labelling technique. Drugs Today 1992; 28 Suppl. A: 45-53
35. Kontoghiorghes GJ, Sheppard L, Chambers S. New synthetic approach and iron chelation studies of 1-alkyl-2-methyl-3-hydroxypyrid-4-ones. Arzneimittel Forschung 1987; 37: 1099-102
36. Kontoghiorghes GJ, Chambers S, Hoffbrand AV. Comparative study of iron mobilization from haemosiderin, ferritin and iron(III) precipitates by chelators. Biochem J 1987 Jan 1; 241: 87-92
37. Shalev O, Rcpka T, Goldfarb A, et al. Deferiprone (L1) chelates pathologic iron deposits from membranes of intact thalassemic and sickle red blood cells both in vitro and in vivo. Blood 1995 Sep 1; 86: 2008-13
38. De Franceschi L, Shalev O, Riga A, et al. Deferiprone therapy in homozygous human β-thalassaemia removes erythrocyte membrane free iron and reduces KCI cotransport activity. J Lab Clin Med 1999; 133: 64-9
39. Diav-Citrin O, Koren G. Oral iron chelation with deferiprone. Pediatr Clin North Am 1997 Feb; 44: 235-47
40. van der Kraaij AM, van Fijk HG, Koster JF. Prevention of postischemic cardiac injury by the orally active iron chelator 1,2-dimethyl-3-hydroxy-4-pyridone (L1) and the antioxidant (+)-cyanidanol-3. Circulation 1989 Jul; 80: 158-64
41. Motekitis RJ, Martell AE. Stabilization of the iron (III) chelates of 1,2-dymethyl-3-hydroxypyrid-4-ones and related ligands. Inorg Chim Acta 1991; 183: 71-80
42. Cragg L, Hebbel RP, Solovey A, et al. The iron chelator L1 potentiates iron-mediated oxidative DNA damage [abstract]. Blood 1996 Nov 15; 88 (10 Suppl. 1, Pt 1): 646
43. Matthews AJ, Vercellotti GM, Menchaca HJ, et al. Iron and atherosclerosis: inhibition by the iron chelator deferiprone (II). J Surg Res 1997 Nov; 73: 35-40
44. Shalev O, Choong S, Goldfarb A, et al. Deferiprone (L1) attenuates methemoglobin formation in metabolically stressed normal (N) and β-thalassemic (T) RBC [abstract]. Blood 1998; 92 (Suppl. 1 Pt 1): 529a
45. Browne PV, Shalev O, Choong S, et al. Amelioration of red cell pathobiology and hemolysis in murine thalassemia via deferiprone-mediated removal of red blood cell membrane iron [abstract]. Blood 1995 Nov 15; 86 Suppl. 1: 482a
46. Korkina LG, Afanas' ev IB, Deeva IB, et al. Free radical status of blood of patients with iron overload: the effect of chelating treatment. Drugs Today 1992; 28 Suppl. A: 137-41
47. Naves DML, Elorrianga R, Canteros A, et al. Effect of desferrioxamine and deferiprone (L1) on the proliferation of MG-63 bone cells and on phosphatase alkaline activity. Nephrol Dial Transplant 1998, 13 Suppl. 3: 23-8
48. Blatt J, Taylor SR, Kontoghiorghes GJ. Comparison of activity of deferoxamine with that of oral iron chelators against human neuroblastoma cell lines. Cancer Res 1989 Jun 1; 49: 2925-7
49. 49: Hileti D, Panayiotidis P, Hoffbrand AV. Iron chelators induce apoptosis in proliferating cells. Br J Haematol 1995 Jan; 89: 181-7
50. Cunningham JM, Al-Refaie FN, Hunter AE, et al. Differential toxicity of α-keto hydroxypyridine iron chelators and desferrioxamine to human haemopoietic precursors in vitro. Eur J Haematol 1994 Mar; 52: 176-9
51. 1) and desferrioxamine on myelopoiesis using a liquid culture system. Br J Haematol 1994 May; 87: 196-8
52. Loebstein R, Diav-Citrin O, Atanackovic G, et al. Deferiprone-induced agranulocytosis: a critical review of five rechallenged cases. Clin Drug Invest 1997 Jun; 13: 345-9
53. 1. Lancet 1993 Apr 24; 341: 1088
54. Porter JB, Hoyes KP, Abeysinghe RD, et al. Future of oral iron chelator deferiprone (L1). Lancet 1991; 341: 1480
55. Link G, Pinson A, Hershko C. Ability of the orally effective iron chelators dimethyl-and diethyl-hydroxypyrid-4-one and of deferoxamine to restore sarcolemmal thiolic enzyme activity in iron-loaded heart cells. Blood 1994 May 1; 83: 2692-7
56. Pope E, Berkovitch M, Klein J, et al. Salivary measurement of deferiprone concentrations and correlation with serum levels. Ther Drug Monit 1997 Feb; 19: 95-7
57. Diav-Citrin O, Atanackovic G, Loebstein R, et al. An investigation into variability in the response to deferiprone in patients with thalassemia major. Ther Drug Monit 1999; 21: 74-81
58. Hileti D, Shalev O, Telfer PT, et al. L1 (deferiprone) accumulates within thalassaemic but not normal or sickle red blood cells [abstract]. Blood 1995 Nov 15; 86 Suppl. I: 483a
59. Hileti D, Ward RJ, Peters TJ, et al. Pharmacokinetics, tissue distribution and cell uptake of 14C-labelled oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in the rat [abstract]. Br J Haematol 1995; 89 Suppl. I: 87
60. Singh S, Epemolu RO, Dobbin PS, et al. Urinary metabolic profiles in human and rat of 1,2-dimethyl-and 1,2-diethyl-substituted 3-hydroxypyridin-4-ones. Drug Metab Dispos 1992 Mar-Apr; 20: 256-61
61. 1) in thalassemia major. Blood 1992 Aug 1; 80: 593-9
62. Al-Refaie FN, Hershko C, Hoffbrand AV, et al. Results of long term deferiprone (L1) therapy; a report by the International Study Group on Oral Iron Chelators. Br J Haematol 1995 Sep; 91: 224-9
63. Hoffbrand AV, Al-Refaie F, Davis H, et al. Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients. Blood 1998 Jan 1; 91: 295-300
64. Kersten MJ, Lange R, Smeets MEP, et al. Long-term treatment of transfusional iron overload with the oral iron chelator deferiprone (L1): a Dutch multicenter trial. Ann Hematol 1996 Nov; 73: 247-52
65. Longo F, Fischer R, Engelhardt R, et al. Iron balance in thalassemia patients treated with deferiprone [abstract]. Blood 1998; 92 (10 Suppl. 1, Pt 1): 325a
66. Mazza P, Amurri B, Lazzari G, et al. Oral iron chelating therapy. A single center interim report on deferiprone (L1) in thalassaemia. Haematologica 1998; 83: 496-501
67. Olivieri NF, Brittenham GM, Matsui D, et al. Iron-chelation therapy with oral deferiprone in patients with thalassemia major. N Engl J Med 1995 Apr 6; 332: 918-22
68. Taher A, Chamoun S, Koussa S, et al. Efficacy and tolerance of the oral iron chelator, deferiprone, in thalassemia: the Lebanese experience [in abstract]. Br J Haematol 1998; 102: 55
69. Cohen A, Galanello R, Piga A, et al. A multi-center safety trial of the oral iron chelator deferiprone. Ann N Y Acad Sci 1998; 850: 223-6
70. Olivieri NF, Nathan DG, MacMillan JH, et al. Survival in medically treated patients with homozygous β thalassaemia. N Engl j Med 1994; 331: 554-78
71. Brittenham GM, Griffith PM, Nienhuis AW, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassaemia major. N Engl J Med 1994 Sep 1; 331: 567-73
72. Brittenham GM, Cohen AR, McLaren CE, et al. Hepatic iron stores and plasma ferritin concentration in patients with sickle cell anemia and thalassemia major. Am J Hematol 1993; 42: 81-5
73. 1. Br J Haematol 1992 Oct; 82: 431-6
74. Olivieri NF, Brittenham GM, McLaren CE, et al. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassaemia major. N Engl J Med 1998; 339: 417-23
75. Ambu R, Crisponi G, Sciot R, et al. Uneven hepatic iron and phosphorus distribution in beta-thalassemia. J Hepatol 1995: 544-50
76. Villeneuve J-P, Bilodeau M, Lepage K, et al. Variability in hepatic iron concentration measured from needle-biopsy specimens. J Hepatol 1996 Aug; 25 (2): 172-7
77. Faa G, Sciot R, Farci AMG, et al. Iron concentration and distribution in the newborn liver. Liver 1994; 14: 193-9
78. Angelueci H, Baronciani D, Lucarelli G. Needle liver biopsy in thalassaemia: analyses of diagnostic accuracy and safety in 1184 consecutive biopsies. Br J Haematol 1995; 89: 757-61
79. Brittenham GM, Farrell DE, Harris JW, et al. Magnetic-susceptibility measurement of human iron stores. N Engl J Med 1982; 307: 1671-5
80. Nielsen P, Fischer R, Engelhardt R, et al. Liver iron stores in patients with secondary haemosiderosis under iron chelation therapy with deferoxamine or deferiprone. Br J Haematol 1995 Dec; 91: 827-33
81. Collins AF, Fassos FF, Stobie S, et al. Iron-balance and dose-response studies of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron-loaded patients w:ith sickle cell disease. Blood 1994 Apr 15; 83: 2329-33
82. Grady RW, Hilgartner MW, Giardina PJ. Deferiprone: its efficacy relative to that of Desferal [abstract]. Blood 1996 Nov 15; 88 (10 Suppl. 1, Pt 1: 310
83. Grady RW, Giardina PJ. Deferiprone (DFP) and desferal (DFO): are they complementary? 8th International Conference Oral Chelation in the Treatment of Thalassaemia and Other Diseases; 1997 Sep 19-21; Corfu
84. Olivieri NF, Koren G, Hermann C, et al. Comparison of oral iron dictator L1 and desferrioxamine in iron-loaded patients. Lancet 1990 Nov 24; 336: 1275-9
85. 1). Eur J Pharmacol 1999; 55: 1-6
86. Wonke B, Wright C, Hoffbrand AV. Combined therapy with deferiprone and desferrioxamine. Br J Haematol 1998; 103: 361-4
87. Olivieri NF, Iron CRG. Randomized trial of deferiprone (L1) and deferoxamine (DFO) in thalassemia major [abstract]. Blood 1996 Nov 15; 88 (10 Suppl. 1, Pt 1); 651
88. Tondury P, Kontoghiorghes GJ, Ridolfi-Luthy A, et al. L1 (1,2-dimethyl-3-hydroxypyrid-4-one) for oral iron chelation in patients with beta-thalassaemia major. Br J Haematol 1990 Dec; 76: 550-3
89. Olivieri NF, Koren G, Matsui D, et al. Reduction of tissue iron stores and normalization of serum ferritin during treatment with the oral iron chelator L1 in thalassemia intermedia Blood 1992 May 15; 79: 2741-8
90. Olivieri NF, Belluzzo N, Muraca M, et al. Evidence of reduction in hepatic, cardiac and pituitary iron stores in patients with thalassaemia major during long-term therapy with the orally active iron chelating agent L1. American Society of Haematology 36th Annual Meeting; 1994 December 2-6; Nashville
91. Olivieri NF, Brittenham GM, Armstrong SAM, et al. First prospective randomized trial of the iron chelators deferiprone [L1] and deferoxamine [abstract]. Blood 1995 Nov 15; 86 Suppl. 1: 249a
92. Tricta F, Dougherty G, Diav-Citrin O, et al. Randomized trial of deferiprone (L1) and deferoxamine (DFO) in thalassemia major [abstract]. 6th International Conference on Thalassemia and the Haemoglobinopathies; 1997 April 5-10; Malta
93. Maggio A, Calabrese A, Capra M, et al. Efficacy of L1 (deferiprone) versus desfemoxamine shown by a randomized multicentric clinical trial [abstract]. 7th International Conference on Thalassaemia and the Haemoglobinopathies; 1999 May 31-June 4; Bangkok, Thailand
94. Grady RW, Berdoukas VA, Giardina PJ. Iron chelation: combined therapy could be a better approach [abstract]. Blood 1998; 92 Suppl. 1 Pt 2: 16b
95. Matsui D, Hermann C, Klein J, et al. Critical comparison of novel and existing methods of compliance assessment during a clinical trial of an oral iron chelator. J Clin Pharmacol 1994 Sep; 9: 944-9
96. Olivieri NF, Matsui D, Hermann C. Compliance assessed by the Medication Event Monitoring System. Arch Dis Child 1991 Dec; 66: 1399-402
97. Tricta F, Riga A, Tricta RM, et al. Electronic monitoring of compliance with deferiprone in thalassemia major patients [abstract]. Br J Haematol 1996 Jun; 93 Suppl. 2: 34-5
98. Olivieri NF, Matsui D, Berkovitch M, et al. Superior effectiveness of the oral iron chelator L1 vs subcutaneous deferoxamine in patients with homozygous beta-thalassemia (HBT): the impact of patient compliance during two years of therapy [abstract]. Blood 1991 Suppl. I: 344a
99. Basran RK, Fassos FF, Shaw D, et al. Assessment of the relative quality of life in patients receiving subcutaneous deferoxamine and the orally active iron chelating agent L1 [abstract]. Blood 1994 Nov 15; 84 Suppl. 1: 261a
100. Bartlett AN, Hoffbrand AV, Kontoghiorghes GJ. Long-term trial with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (II). Br J Haematol 1990 Oct; 76: 301-4
101. al-Refaie FN, Wonke B, Hoffbrand AV. Arthropathy in thalassaemia patients receiving deferiprone [letter; comment]. Lancet 1994 Jul 23; 344: 262-3
102. Berkovitch M, Laxer RM, Inman R, et al. Arthropathy in thalassaemia patients receiving deferiprone. Lancet 1994 Jun 11; 343: 1471-2
103. Castriota-Scanderbeg A, Sacco M. Agranulocytosis, arthritis and systemic vasculitis in a patient receiving the oral iron chelator L1 (deferiprone). Br J Haematol 1997 Feb; 96: 254-5
104. Al-Refaie FN, Wonke B, Hoffbrand AV. Deferiprone-associated myelotoxicity. Eur J Haematol 1994 Nov; 53: 298-301
105. Hoffbrand AV, Bartlett AN, Veys PA, et al. Agranulocytosis and thrombocytopenia in patient with Blackfan-Diamond anaemia during oral chelator trial [letter] [see comments]. Lancet 1989 Aug 19; 2: 457
106. Bertola U, Collell M, Piga A, et al. Neutropenia in homozygous β thalassaemia patients on desferrioxamine treatment. 8th International Conference Oral Chelation in the Treatment of Thalassaemia and Other Diseases; 1997 Sep 19-21; Corfu
107. Mehta J, Chablani A, Reporter R, et al. Autoantibodies in thalassaemia major relationship with oral iron chelator L1. J Assoc Physicians India 1993 Jun; 41: 339-41
108. Mehta J, Singhal S, Mehta BC. Deferiprone in iron overload [letter]. N Engl J Med 1995 Aug 31; 333: 597-8
109. Olivieri NF, Matsui D, Liu PP, et al. Oral iron chelation with 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron loaded thalassemia patients. Bone Marrow Transplant 1993; 12 Suppl. 1: 9-11
110. Olivieri NF, Koren G, Freedman MH, et al. Rarity of systemic lupus erythematosus after oral iron chelator L1 [letter]. Lancet 1991 Apr 13; 337: 924
111. Mehta J, Singhal S, Revankar R, et al. Fatal systemic lupus erythematosus in patient taking oral iron chelator L1 [letter]. Lancet 1991 Feb 2; 337: 298
112. Loebstein R, Dalal I, Nisbet-Brown E, et al. Immune function in patients with β thalassaemia receiving the orally active iron-chelating agent deferiprone. Br J Haematol 1997 Sep; 98 (3): 597-600
113. Alrefaie FN, Wonke B, Wickens DG, et al. Zinc concentration in patients with iron overload receiving oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one or desferrioxamine. J Clin Pathol 1994 Jul; 47: 657-60
114. Erer B, Angelucci F, Lucarelli G. HCV infection in thalassemia before and after BMT. Bone Marrow Transplant 1997; 19 Suppl. 2: 155-7
115. Lai ME, Argiolu F, Balaci L, et al. A prospective study of transfusion associated hepatitis in thalassemic children after the introduction of anti-HCV donor screening. Bone Marrow Transplant 1997; 19 Suppt. 2: 158-9
116. Kowdley KV, Kaplan MM. Iron-chelation therapy with oral deferiprone-toxicity or lack of efficacy? N Engl J Med 1998 Aug 13; 339: 468-9
117. Callea F. Iron chelation with oral deferiprone in patients with thalassemia [letter]. N Engl J Med 1998; 339: 1710-1
118. Töndury P, Zimmermann A, Nielsen P, et al. Liver iron and fibrosis during long-term treatmenl with deferiprone in Swiss thalassaemic patients. Br J Haematol 1998 Jun; 101 (3): 413-5
119. Piga A, Facello S, Gaglioti C, et al. No progression of liver fibrosis in thalassemia major during deferiprone or desferrioxamine iron chelation [abstract]. Blood 1998 Nov 15; 92 (10 Suppl. I, Pt 2): 21b
120. Galanello R, Dc Virgilis S, Agus A, et al. Sequential liver fibrosis grading during deferiprone treatment in patients with thalassaemia major. 9th International Conference on Iron Chelation in the Treatment of Thalassacmia und Other Diseases; 1999 Mar 25-28; Hamburg
121. Stella M, Pinzello G, Maggio A. Iron chelation with oral deferiprone in patients with thalassemia. N Engl J Med 1998; 339: 1712
122. Marciani MG, Iani C, Desiato MT, et al. Subclinical auditory and visual involvement during oral deferiprone therapy [letter]. Am J Hematol 1996 Feb; 51: 179-80
123. Chiesi Farmaceutici. Deferiprone Chiesi Farmaceutici. Summary of product characteristics. Parma, Italy, 1999
124. Piga A, Alberti D, Hassan I, et al. Efficacy of a new formulation of desferrioxamine (CGH 749B) given as a subcutaneous bolus injection in transfusion-dependent beta thalassemic patients. Blood 1997 Suppl. 1: 32a
125. Borgna-Pignatti C, Cohen A. Evaluation of a new method of administration of the iron chelating agent deferoxamine. J Pediatr 1997 Jan; 130: 86-8
126. Schnebli HP. CGP 72 670; a new potent, orally active iron chelator. Br J Haematol 1998; 102: 280
127. Olivieri NF. Long-term therapy with deferiprone, Acta Haematol 1996; 95 (1): 37-48
128. Pfannkuch F, Bentley P, Schnebli HP. Future of oral iron chelator deferiprone (L1) (letter). Lancet 1993 Jun 5; 341: 1480
129. Nathan DG. An orally active iron chelator. N Engl J Med 1995 Apr 6; 332: 953-4
130. Kontoghiorghes GJ, Bartlett AN, Sheppard L, et al. Oral iron chelation therapy with deferiprone: monitoring of biochemical, drug and iron excretion changes. Arzneimittel Forschung 1995 Jan; 45: 65-9
131. Olivieri NF, Koren G, Matsui D, et al. Reduction of tissue iron stores and normalization of serum ferrilin during treatment with the oral iron chelator L1 in thalassemia intermedia. Drugs Today 1992; 28 Suppl. A: 123-32